Multiple sclerosis
Do omega-3s improve multiple sclerosis outcomes?
Omega-3s have been studied for MS, but biological plausibility and selected positive reviews do not establish a dependable reduction in relapse or disability.
Updated September 24, 2026 · Editorial attribution: PV Griscom, M.Sc. · Independent clinical review pending
The question behind the headline
Adults with MS; studies of symptoms, disease activity, inflammatory measures and quality of life.
What the finding does—and doesn’t—tell us
Do not equate lower inflammation markers with slower disability progression. Disease-modifying treatment remains a separate clinical decision.
Read the underlying research.
- Effect of omega-3 fatty acids and fish oil supplementation on multiple sclerosis: a systematic review. · 2021 ↗
- Association of Polyunsaturated Fatty Acid Intake on Inflammatory Gene Expression and Multiple Sclerosis: A Systematic Review and Meta-Analysis. · 2022 ↗
Selected sources, not an exhaustive reference list. Research record or abstract screening only; full-text efficacy appraisal is pending. Source publication dates may precede this page’s update date.
Three questions to take forward
- Was the study population similar to the person or situation I have in mind?
- Did it measure an outcome people feel or experience, or only a laboratory marker?
- How do formulation, usual care, absolute benefit and adverse effects change the interpretation?
Study doses describe experiments; they are not personal dosing advice. Explore safety and limitations ↗